Editorials May 8, 2021
The WHO estimates that 25% of global deaths last week occurred in India, a death toll that exceeded 3,700 lives per day.
The WHO estimates that 25% of global deaths last week occurred in India, a death toll that exceeded 3,700 lives per day.
Japan pharma industry opposes U.S. backing for vaccine patent waiver
The Japan Pharmaceutical Manufacturers Association said it is concerned that noneffective products may circulate, and the risk of side effects could increase as well.
The world turns to China for vaccines after India and U.S. stumble
Some experts are worried about the potential impact of widely deploying Chinese shots that have demonstrated lower efficacy rates than those made by Pfizer and Moderna.
Biden's vaccine-patent gambit turns up the heat on drugmakers
By supporting the World Trade Organization process, the U.S. president can satisfy progressives while engaging in talks on a waiver that may never reach consensus.
In a reversal, U.S. backs giving poorer countries access to COVID-19 vaccine patents and tech
"This is a global health crisis, and the extraordinary circumstances of the COVID-19 pandemic call for extraordinary measures," Biden's top trade negotiator said in a statement
White House backs Pfizer’s move to begin vaccine exports
Early U.S. production wasn’t subject to an export ban but was gobbled up entirely by the government, which used wartime powers to prioritize its orders.
Risk from virus variants remains after first Pfizer COVID-19 vaccine, U.K. study finds
A single dose of the vaccine may not generate a sufficient immune response to protect against dominant new variants, except in people who have already been infected with COVID-19.
Japan to approve Moderna vaccine as soon as May 21, report says
The Moderna vaccine would be the second to get approved in Japan and will be used in the nation’s large inoculation centers that will open in Tokyo and Osaka from May 24, the report said.
It will become the second type of shot available in the country after the one developed by Pfizer Inc. if a health ministry panel greenlights it as early as May 20.
With large vaccine studies harder to carry out, regulators look for alternatives
The start of inoculation campaigns has made it difficult for some nations to recruit a sufficient number of test subjects who have no immunity against the coronavirus.
COVID-19 shots come in bulk, but the world needs single servings
Vials full of doses often must be kept in extreme cold, and once opened have to be used quickly, making delivery to smaller, far-flung populations difficult.
Dark horse of vaccine race may be this French biotech
With the other COVID-19 vaccines in Europe focused on the virus’s spike protein, this shot could protect against variants that might compromise others, making it the perfect booster.